{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:51:33Z","timestamp":1785433893255,"version":"3.56.0"},"reference-count":30,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy"},{"id":[{"id":"https:\/\/ror.org\/0391j1294","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Empirical management of acute pyelonephritis in Eastern Europe is increasingly constrained by extended-spectrum \u03b2-lactamase (ESBL)-producing Enterobacterales and by uropathogen phenotypes\u2014such as strong biofilm formation\u2014which may further blunt antimicrobial activity. We aimed to characterise resistance mechanisms, minimum inhibitory concentration (MIC) distributions, biofilm-forming capacity, and the in vitro performance of carbapenem-sparing agents and to test whether these microbiological features improve prediction of clinical failure beyond standard bedside risk scores. We retrospectively analysed 102 Enterobacterales isolates recovered from 129 consecutive culture-confirmed adult pyelonephritis admissions at \u201cVictor Babe\u0219\u201d University Hospital, Timi\u0219oara (March 2022\u2013March 2025). MIC values were determined by Vitek 2 and interpreted using EUCAST v13 breakpoints; ESBL, AmpC, and carbapenemase phenotypes were confirmed by combination disk and modified carbapenem inactivation methods. Biofilm formation was quantified by the microtiter-plate crystal-violet assay. Mediation, Restricted Mean Survival Time (RMST), and decision-curve analyses were used to assess added clinical value. ESBL was confirmed in 30\/102 (29.4%) isolates, AmpC in 9 (8.8%), and carbapenemase in 4 (3.9%). ESBL+ isolates were more often strong biofilm formers (33.3% vs. 12.5%; p = 0.014) and showed a 4- to 16-fold rightward MIC shift for cefepime, piperacillin\u2013tazobactam, and ciprofloxacin. Among carbapenem-sparing agents, ceftazidime\u2013avibactam (96.7% S), fosfomycin (80.0% S), and amikacin (73.3% S) retained the highest activity against ESBL+ isolates. Strong biofilm formation and the ESBL phenotype were independently associated with worse outcomes (adjusted OR 3.5 and 4.7); an exploratory mediation analysis suggested that biofilm formation may explain part of the observed association between the ESBL phenotype and treatment failure and that delayed effective therapy may account for a further portion of this association. A microbiology-enhanced model that added the ESBL phenotype, biofilm strength, and acquisition setting to routine clinical variables improved discrimination over a clinical-only baseline (AUC 0.89 vs. 0.71) and showed a higher net benefit on exploratory decision-curve analysis across the 10\u201340% threshold range. These predictive findings derive from a single-centre cohort with a small number of events and were only internally validated; they require validation in independent cohorts before any clinical application can be considered. The ESBL phenotype and strong biofilm formation were each independently associated with worse outcomes in pyelonephritis and may help identify candidate isolates for carbapenem-sparing strategies anchored on ceftazidime\u2013avibactam, fosfomycin, and amikacin; given the observational, single-centre design, these associations should be regarded as hypothesis-generating.<\/jats:p>","DOI":"10.3390\/microorganisms14061287","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T02:32:46Z","timestamp":1780885966000},"page":"1287","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenotypic Resistance Profiles, Biofilm Formation, and In Vitro Carbapenem-Sparing Antimicrobial Activity in Enterobacterales Causing Acute Pyelonephritis"],"prefix":"10.3390","volume":"14","author":[{"given":"Livia","family":"Stanga","sequence":"first","affiliation":[{"name":"Discipline of Microbiology, Faculty of Medicine, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidiu","family":"Rosca","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia Georgiana","family":"Bogdan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8619-0479","authenticated-orcid":false,"given":"Ciprian Ilie","family":"Ro\u0219ca","sequence":"additional","affiliation":[{"name":"Department V\u2014Internal Medicine I, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-1253","authenticated-orcid":false,"given":"Horia Silviu","family":"Branea","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I\u2014Medical Semiotics II, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia Vidi\u021ba","family":"Gurban","sequence":"additional","affiliation":[{"name":"Department IV\u2014Biochemistry and Pharmacology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"ref_1","unstructured":"European Association of Urology (2026, March 11). EAU Guidelines on Urological Infections. Available online: https:\/\/uroweb.org\/guidelines\/urological-infections."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat. Rev. Urol."},{"key":"ref_3","unstructured":"European Centre for Disease Prevention and Control (2024). Antimicrobial Resistance in the EU\/EEA (EARS-Net)\u2014Annual Epidemiological Report for 2023."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.cmi.2022.02.024","article-title":"How to: ECOFFs\u2014The why, the how and the don\u2019ts of EUCAST epidemiological cutoff values","volume":"28","author":"Kahlmeter","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/jac\/dkg312","article-title":"European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria","volume":"52","author":"Kahlmeter","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_7","unstructured":"EUCAST (2023). Breakpoint Tables for Interpretation of MICs and Zone Diameters, EUCAST. Version 13.0."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/j.1600-0463.2007.apm_630.x","article-title":"Quantification of biofilm in microtiter plates: Overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci","volume":"115","author":"Hola","year":"2007","journal-title":"APMIS"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"543974","DOI":"10.1155\/2014\/543974","article-title":"Importance of biofilms in urinary tract infections: New therapeutic approaches","volume":"2014","author":"Soto","year":"2014","journal-title":"Adv. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13756-019-0533-3","article-title":"Antibiotics versus biofilm: An emerging battleground in microbial communities","volume":"8","author":"Sharma","year":"2019","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"ESCMID guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli","volume":"28","author":"Paul","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"ciae403","DOI":"10.1093\/cid\/ciae403","article-title":"Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections","volume":"79","author":"Tamma","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"iv23","DOI":"10.1093\/jac\/dkab352","article-title":"Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections","volume":"76","author":"Bassetti","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1037\/a0020761","article-title":"A general approach to causal mediation analysis","volume":"15","author":"Imai","year":"2010","journal-title":"Psychol. Methods"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","article-title":"Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis","volume":"32","author":"Uno","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: A novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med. Decis. Mak."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjms.2018.11.009","article-title":"Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status from Serious Gram-negative Bacterial Infections","volume":"357","author":"Bonine","year":"2019","journal-title":"Am. J. Med. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.chest.2020.03.087","article-title":"A Systematic Review of the Effect of Delayed Appropriate Antibiotic Treatment on the Outcomes of Patients with Severe Bacterial Infections","volume":"158","author":"Zasowski","year":"2020","journal-title":"Chest"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Petca, R.C., Mare\u0219, C., Petca, A., Negoi\u021b\u0103, S., Popescu, R.-I., Bo\u021b, M., Barab\u00e1s, E., and Chibelean, C.B. (2020). Spectrum and Antibiotic Resistance of Uropathogens in Romanian Females. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080472"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae: An emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.euf.2018.11.003","article-title":"Management of urosepsis in 2018","volume":"5","author":"Bonkat","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the EEA in 2015: A population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrmicro821","article-title":"Bacterial biofilms: From the natural environment to infectious diseases","volume":"2","author":"Costerton","year":"2004","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime\u2013avibactam for the treatment of serious Gram-negative infections with limited treatment options: A systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/jac\/dkv086","article-title":"Infections caused by KPC-producing Klebsiella pneumoniae: Differences in therapy and mortality in a multicentre study","volume":"70","author":"Tumbarello","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1128\/AAC.02429-13","article-title":"Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., and Poulakou, G. (2019). The \u2018old\u2019 and the \u2018new\u2019 antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Front. Public Health, 7.","DOI":"10.3389\/fpubh.2019.00151"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41579-019-0288-0","article-title":"The global preclinical antibacterial pipeline","volume":"18","author":"Theuretzbacher","year":"2020","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/6\/1287\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T03:07:41Z","timestamp":1780888061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/6\/1287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":30,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["microorganisms14061287"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14061287","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}